December 21, 2017

Stanton A. Glantz, PhD

Public comment submitting Reuters story on PMI irregulatities in IQOS clinical studies to PMI MRTP docket

Lauren Lempert submitted this comment to FDA on December 20, 2017.  The comment Tracking Number is 1k1-90gh-rnjp.
Reuters published a special report on December 20, 2017 identifying several irregularities in Philip Morris' IQOS research. The kind of industry behavior documented in this report is questionable but not new, and FDA should consider this when making a determination on PMI's IQOS applications. See attached Reuters report and PMI's 10-Year Corporate Affairs Objectives & Strategies report discussed in Reuters report.
Uploaded File(s):

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.